About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 11 results
Filters: Keyword is Quality of Life  [Clear All Filters]
2014
J. A. Roth, Bensink, M. E., O'Donnell, P. V., Fuchs, E. J., Eapen, M., and Ramsey, S. D., Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer., J Comp Eff Res, vol. 3, no. 2, pp. 135-44, 2014.
P. B. Jacobsen, Le-Rademacher, J., Jim, H., Syrjala, K., Wingard, J. R., Logan, B., Wu, J., Majhail, N. S., Wood, W., J Rizzo, D., Geller, N. L., Kitko, C., Faber, E., Abidi, M. H., Slater, S., Horowitz, M. M., and Lee, S. J., Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902., Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1530-6, 2014.
G. E. Switzer, Bruce, J. G., Harrington, D., Haagenson, M., Drexler, R., Foley, A., Confer, D., Bishop, M., Anderlini, P., Rowley, S., Leitman, S. F., Anasetti, C., and Wingard, J. R., Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201., Biol Blood Marrow Transplant, vol. 20, no. 1, pp. 118-27, 2014.
W. Saber, Le Rademacher, J., Sekeres, M., Logan, B., Lewis, M., Mendizabal, A., Leifer, E., Appelbaum, F. R., Horowitz, M. M., Nakamura, R., and Cutler, C. S., Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.